📣 Registration is open for the Urology Times Expert APProach Summit!

Join us in Chicago for a one-day, expert-led program designed for emerging uro-oncology nurse practitioners and physician assistants.

📍 Hyatt Centric Chicago Magnificent Mile
📅 Saturday, November 7, 2026 Register now and be part of the conversation! registration.urologytimes.com/clinical-forum…

🚨 ENZARAD (ANZUP 1303): 2 years of enzalutamide did not improve metastasis-free survival when added to RT + ADT in high-risk/locally advanced #prostatecancer 🚨

@JCO_ASCO

👥 802 pts, high-risk localized or locally advanced PCa (incl cN1)
📊 Open-label phase 3 RCT, definitive 💊 Enzalutamide 160mg daily x24 mo vs older NSAA x6 mo
⏱️ Median f/u 92 mo

✅ 8-yr MFS on conventional imaging 74% vs 72%, HR 0.88 (0.67-1.15), P=0.34, not significant
✅ No OS benefit
✅ Prespecified subgroup w/ planned pelvic nodal RT (n=324): HR 0.47 (0.29-0.76), Padj=0.004

⚠️ Subgroup signal is hypothesis-generating; grade 3-5 AEs 46% in both arms

🎯 Enzalutamide on top of RT + 2 yr ADT did not improve outcomes overall, potential signal with pelvic nodal RT subgroup
🔗 doi.org/10.1200/JCO-26…
@urotoday @UrologyTimes @PCF_Science @SbrtSean @ChrisSweens1 @Prof_IanD @UroOnc @SUO_YUO

🚨 PROTEUS substudy (@EUplatinum): perioperative apalutamide + ADT improves event-free survival vs radical prostatectomy alone in high-risk/locally advanced #prostatecancer, 🧵 1/3 🚨

👥 408 pts, high-risk localized or locally advanced PCa, fit for surgery
📊 Open-label phase 3 3
💊 Perioperative (neoadj + adj) apalutamide + ADT (n=102) vs RP alone (n=306)
⏱️ Median f/u 37.4 mo
⭐️Event = BCR or imaging-based recurrence

✅ 3-yr EFS 63% vs 41%, HR 0.38 (0.26-0.55), p<0.001
✅ MFS by conventional or PSMA PET 87% vs 78%, HR 0.49 (0.26-0.90)
✅ But MFS by conventional imaging alone: similar, 94% vs 92% (p=0.5)

⚠️Caution in interpretation - See thread 👇

🔗 doi.org/10.1016/j.euru…

@PCFnews @PCF_Science @urotoday @UrologyTimes @TylerSbrt @renalandurology @Uroweb @JackAndrewsMD

Investigators are proceeding to the final efficacy analysis for cohort A of the QUILT-2.005 trial, assessing nogapendekin alfa inbakicept plus BCG vs BCG alone in patients with BCG-naïve NMIBC. #blcsm urologytimes.com/view/nogapende…

WATCH: Alicia Morgans, MD, MPH, (@CaPsurvivorship) highlights key prostate cancer data from #ESMO26. | @DanaFarber_GU urologytimes.com/view/alicia-mo…

The target enrollment has been met in the phase 3 CLARIFY trial evaluating 64Cu-SAR-bisPSMA PET for detecting pelvic lymph node metastases in patients with high-risk prostate cancer prior to radical prostatectomy. #pcsm urologytimes.com/view/clarify-t…

What can clinicians learn from negative phase 3 trials of triplet regimens in advanced RCC? In this Q&amp;A, Brian Rini, MD, FASCO, (@brian_rini) discusses key lessons from LITESPARK-012 and questions for future treatment development. #ESMO26 urologytimes.com/view/litespark…

WATCH: Alberto Briganti, MD, PhD, (@Albert0Briganti) discusses results from the PROTEUS Substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer. #ESMO26 urologytimes.com/view/alberto-b…

From the midterm elections to AI and ancillary services, explore the key conversations that will be happening in Chicago next week at the #LUGPA2026 Annual Meeting @UrologyTimes @UroDrBen

Listen to the feature interview: urologytimes.com/view/lugpa-202…

#PhysicianLedPractice #urology

Great discussion with @MayoUrology's Dr Paras Shah, on the evolving treatment of high-risk NMIBC and a recap of the recent North Central Section Meeting of the AUA!
@AmerUrological #NCSAUA26 #NMIBC @MayoCancerCare #BladderCancer

JNJ-6143, a first-in-class RIPTAC molecule, demonstrated activity and an encouraging safety profile in patients with heavily pretreated mCRPC, according to phase 1 data presented at #ESMO26. | @BGarmezy urologytimes.com/view/novel-rip…

AUA North Central Section Meeting Recap x.com/i/broadcasts/1…

#ESMO26: Durvalumab plus BCG improved disease-free survival vs BCG alone in patients with BCG-naïve, high-risk, papillary-only NMIBC, according to a subgroup analysis of the POTOMAC trial.
urologytimes.com/view/durvaluma…

🚨 CAPItello-281 OS update: capivasertib + abiraterone extended survival by ~11 mo in PTEN-deficient de novo mHSPC #prostatecancer 🚨

@Annals_Oncology

👥 n=1012, PTEN-deficient de novo metastatic hormone-sensitive PCa
📊 Phase 3 RCT, updated OS (descriptive, 42% maturity)
💊 one + ADT vs placebo + abiraterone + ADT
⏱️ +17 mo f/u, data cutoff Mar 2026

✅ Median OS 57.4 vs 46.5 mo, HR 0.82 (95% CI 0.68-0.99), p=0.044
✅ Deaths 38.5% vs 44.8%; median OS reached in both arms for the first time
✅ Deeper signal with deeper PTEN loss

⚠️ Descriptive analysis at 42% maturity w/ CI upper bound at 0.99,
🎯 Adding the AKT inhibitor to abiraterone improved OS in PTEN-deficient subset

🔗 doi.org/10.1016/j.anno…
@UroOnc @urotoday @UrologyTimes @PCF_Science

Join us tonight at 7pm ET as Paras H. Shah, MD, recaps notable data presented at the 2026 AUA North Central Section Annual Meeting. #NCSAUA26

Stay tuned! 🎙️ x.com/i/broadcasts/1…

BREAKING 🚨 : The @FDA has approved talazoparib plus enzalutamide for adult patients with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with HRR gene mutations.

🔗: urologytimes.com/view/talazopar…

WATCH: Daniel Heng, MD, MPH, FRCPC, (@DrDanielHeng) highlights final results from LITESPARK-011, which evaluated belzutifan plus lenvatinib vs cabozantinib in patients with advanced ccRCC following anti-PD-(L)1 therapy. #ESMO26 urologytimes.com/view/daniel-he…

Join us on October 27 at 7pm ET as Paras H. Shah, MD, recaps notable data presented at the 2026 AUA North Central Section Annual Meeting. #NCSAUA26

Stay tuned! 🎙️: x.com/i/broadcasts/1…

PROTEUS Substudy at #ESMO26: Adding perioperative APA + ADT to radical prostatectomy with pelvic lymph node dissection significantly extended EFS compared with surgery alone in patients with high-risk localized or locally advanced prostate cancer. #pcsm urologytimes.com/view/proteus-s…